Physician profile
Ryan M Smith
NPI 1245541721
$92,215.70
in general payments reported to CMS, 2019-2025
8 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $4,384 · 2021: $5,951 · 2022: $40K · 2023: $14K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Honoraria: $11K · Travel and Lodging: $2,316 · Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,360.00 |
| Honoraria | $11,475.00 |
| Travel and Lodging | $2,315.95 |
| Food and Beverage | $1,072.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $42,806.39 | 2021-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $34,322.04 | 2019-2023 | Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $13,016.49 | 2025 | Symbravo |
| Janssen Pharmaceuticals, INC | $1,559.94 | 2019-2022 | |
| Abbvie INC. | $227.91 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $203.13 | 2019 | |
| Allergan, INC. | $79.80 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.